Navigation Links
Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
Date:11/20/2008

a Dr. Reshma Mahtani MD Anderson, Houston, Texas Dr. Banu Arun Memorial Cancer Institute, Hollywood, Florida Dr. Alejandra Perez Montefiore Medical Center, Bronx, New York Dr. Tianhong Li Ohio State University, Columbus, Ohio Dr. Ewa Mrozek St. Vincent's Medical Center, New York, New York Dr. Paula Klein University of California, San Francisco, California Dr. Hope Rugo University of Chicago, Chicago, Illinois Dr. Gini Fleming University of Miami, Miami, Florida Dr. Alberto Montero University of Pittsburg Magee Women's Hospital, Pittsburg, Pennsylvania Dr. Adam Brufsky University of Southern California, Los Angeles, California Dr. Agustin Garcia University of Texas, Southwestern, Dallas, Texas Dr. Jenny Li

BZL101

BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact. Normal cells depend primarily on the citric acid cycle (>85%) and very little on glycolysis (<7%) for energy production. Cancer cells depend largely on glycolysis (>85%) for energy production. BZL101 stops the production cycle of energy in cancer cells by inhibiting glycolysis. This leads to DNA damage and cell death in cancer cells while normal cells remain unharmed.

There are currently no effective therapeutic cures for advanced breast cancer and treatment is primarily aimed at palliation of symptoms as well as improving overall survival. Over 200,000 women in the United States are diagnosed with breast cancer each year and breast cancer is the second leading cause of cancer death in women. Although survival after breast cancer treatment is improving, there are s
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
2. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
3. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
4. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
7. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
8. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
9. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
10. Lytix Presents LTX-109 Anti-Microbial Data at ICAAC
11. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 RoundTable Healthcare Partners ("RoundTable"), an ... healthcare industry, announced today the sale of Vesta ... Lubrizol, a Berkshire Hathaway company, is a specialty ... customers in the global transportation, industrial and consumer ... Vesta is an ISO-13485 certified medical ...
(Date:8/1/2014)... NORTH CHICAGO , Ill. and PALO ... (NYSE: ABBV) and Cystic Fibrosis Research, Inc. (CFRI) today announced ... in the cystic fibrosis (CF) community through the CFChef ... to September 15, 2014, as part of AbbVie,s CFChef ... caregivers – to encourage patients to maintain a healthy ...
(Date:8/1/2014)... Mass. , Aug. 1, 2014  NxStage Medical, Inc. ... dialysis products, today announced that Jeffrey H. Burbank , ... Officer, will present at the 34 th Annual Canaccord ... Boston, MA , on Wednesday, August 13 th ... will be made available at http://ir.nxstage.com/ .  ...
Breaking Medicine Technology:RoundTable Healthcare Partners Announces Sale of Vesta Funding, Inc. to The Lubrizol Corporation 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2
... 6, 2012  PAREXEL International Corporation (NASDAQ: PRXL ... that Ramita Tandon, Global Head, Late Phase Clinical Trials ... Operations at PAREXEL will address innovative approaches to late ... ( SCOPE ), to be held February 7-9, 2012 ...
... New York, February 6, 2012 In the news ... of USD 6.8 billion in 2015, China Osteoporosis Market Will be ... 11:30 GMT, by Transparency Market Research over PR Newswire, we are ... "Market Size of USD 6.8 billion" has been changed to "Market ...
Cached Medicine Technology:PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives 2PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives 3PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives 4CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015 2CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015 3CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015 4
(Date:8/1/2014)... at the University of California, San Diego School of ... in chili peppers produces chronic activation of a ... a reaction that ultimately reduces the risk of colorectal ... 1, 2014 issue of The Journal of Clinical ... TRPV1, was originally discovered in sensory neurons, where it ...
(Date:8/1/2014)... 2014 Stryker hip lawsuits ( ... 2012 Rejuvenate and ABG II Modular-Neck Hip Stem ... Bergen County Superior Court, Bernstein Liebhard LLP reports. ... Court has issued a Final Amended Stipulated ... hard copy and electronic materials produced by any ...
(Date:8/1/2014)... MN (PRWEB) August 01, 2014 Summer is ... are most active during the summer, and they can be ... Minnesota is ready to help all their customers get rid ... between 3,000 and 6,000 eggs in the summer, which is ... to live in tall grass and woodland areas and carry ...
(Date:8/1/2014)... 01, 2014 The American Telemedicine ... Harper (R-MS), and Peter Welch (D-VT), for their ... Telehealth Parity Act of 2014, which improves telemedicine ... effort to improve healthcare access and affordability using ... of ATA. "These cost-saving provisions are critical to ...
(Date:8/1/2014)... The "Antimicrobial Coatings Market by ... Oxide, Titanium Dioxide, and Zinc Omadine), Application (Indoor ... & Beverages, Textiles, and others), & Geography (North ... and Forecasts to 2018" analyzes the Antimicrobial Coatings ... trends in the diverse geographical regions. , Browse ...
Breaking Medicine News(10 mins):Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Tis the Season for Tick Prevention 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4
... NEW YORK, March 19 More than 90% ... market, due to the lack of,effectiveness or adverse ... positives could be avoided with pre-clinical tests using ... to,Kalorama Information,s new report Stem Cells: Worldwide Markets ...
... 19, 2008 The Russell Berrie Foundation has donated ... Hospital, as part of a focused effort to provide ... research initiatives, toward a cure, the Medical Center gratefully ... diabetes is a disease in which the bodys failure ...
... on Food Safety and Quality, ANN ARBOR, ... Spartan Stores is the largest supermarket chain in ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070816/DCTH039LOGO ), Spartan ... and,retailers, is going beyond standard Food Code requirements ...
... of Howard G. Smith,announces that a securities class action ... purchased the publicly traded securities of Vertex,Pharmaceuticals Inc. ("Vertex" ... 2007 and November 2, 2007, inclusive (the "Class Period"). ... District Court for the,District of Massachusetts., The Complaint ...
... join panel after key ground rules established, OAKLAND, ... employed by Sutter Health,s,California Pacific Medical Center and St. ... Panel formed to develop a plan for the future ... panel after its co-chairs, with the,agreement of city leaders ...
... altered form of natural compound found in heparin samples ... officials say they,ve identified the contaminant found in the ... allergic reactions and possibly 19 deaths in the United ... oversulfated condroitin sulfate, but U.S. Food and Drug Administration ...
Cached Medicine News:Health News:Stem Cell Technology Offers Promise of Huge Savings for Drug Developers 2Health News:Columbia University Medical Center/NYPH receive $28 million donation toward curing diabetes 2Health News:Columbia University Medical Center/NYPH receive $28 million donation toward curing diabetes 3Health News:Spartan Stores Becomes Largest U.S. Supermarket Chain to Receive NSF Shop Fresh(TM) Certification 2Health News:Spartan Stores Becomes Largest U.S. Supermarket Chain to Receive NSF Shop Fresh(TM) Certification 3Health News:UHW Joins Blue Ribbon Panel on the Future of St. Luke's Hospital 2Health News:FDA Identifies Contaminant in Blood-Thinning Drug 2Health News:FDA Identifies Contaminant in Blood-Thinning Drug 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: